Tag - BCLI

Markets

Maxim ups BrainStorm Cell Therapeutics to buy from hold; PT $12

Maxim Group upgraded BrainStorm Cell Therapeutics (NASDAQ:BCLI) to “buy” from “hold” with a price target of $12, citing a pullback in the stock since the ALS Phase 3 results in the fourth quarter of 2020, opportunities...

February 4, 2021

Developments

BrainStorm NurOwn flunks Phase 3 ALS trial

BrainStorm Cell Therapeutics’ (NASDAQ:BCLI) NurOwn failed to meet its primary and secondary endpoints in a Phase 3 amyotrophic lateral sclerosis (ALS) trial. NurOwn consists of mesenchymal stromal cells (MSCs) that have...

November 17, 2020

Developments

BrainStorm completes enrollment of Phase 3 ALS trial

BrainStorm Cell Therapeutics (NASDAQ:BCLI) completed enrollment of its 200-patient Phase 3 trial evaluating NurOwn for the treatment of amyotrophic lateral sclerosis (ALS). The NurOwn process involves isolating...

October 11, 2019

Tag - BCLI

Maxim ups BrainStorm Cell Therapeutics to buy from hold; PT $12

BrainStorm NurOwn flunks Phase 3 ALS trial

BrainStorm completes enrollment of Phase 3 ALS trial

General

More